Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT ID: NCT00068315
Last Updated: 2013-09-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
18 participants
INTERVENTIONAL
2003-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Determine the safety and toxicity of bortezomib and fludarabine with or without rituximab in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
II. Determine the maximum tolerated dose of bortezomib in combination with fludarabine in these patients.
III. Determine the biological effect of this regimen on apoptotic markers, cell cycle kinase inhibitors, and DNA repair in these patients.
OUTLINE: This is a multicenter, dose-escalation study of bortezomib.
Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and fludarabine IV over 30 minutes on days 1-3 or 1-5. Patients may also receive rituximab IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (bortezomib, fludarabine, rituximab)
Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and fludarabine IV over 30 minutes on days 1-3 or 1-5. Patients may also receive rituximab IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
bortezomib
Given IV
fludarabine phosphate
Given IV
rituximab
Given IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bortezomib
Given IV
fludarabine phosphate
Given IV
rituximab
Given IV
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Follicular lymphoma:
* Grade I follicular small cleaved cell;
* Grade II follicular mixed cell;
* Grade II follicular large cell;
* Diffuse small cleaved cell;
* Small lymphocytic lymphoma;
* Lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia)
* AND
* Extranodal marginal zone B-cell lymphoma (mucosa-associated lymphoid tissue \[MALT\] lymphoma);
* Nodal marginal zone B-cell lymphoma (monocytoid B-cell lymphoma);
* Splenic marginal zone lymphoma (splenic lymphoma with villous lymphocytes);
* Mantle cell lymphoma:
* No blastic phase mantle cell lymphoma
* Relapsed or refractory, progressive disease:
* First, second, or third relapse
* Measurable disease, meeting 1 of the following criteria:
* At least 1 unidimensionally measurable lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan (for NHL patients);
* OR:
* Lymphocytosis \> 50,000/mm3 OR evidence of progressive bone marrow infiltration failure (e.g., hemoglobin 10 g/dL) OR thrombocytopenia (i.e., platelet count \< 100,000/mm3) with \> 30% infiltration of bone marrow by leukemia (for CLL patients)
* No measurable lymphadenopathy (for CLL and Waldenstrom's macroglobulinemia patients)
* No evidence of CNS lymphoma
* Performance status:
* ECOG 0-2
* Life expectancy:
* More than 12 weeks
* No history of uncontrolled orthostatic hypotension
* No symptomatic congestive heart failure
* No unstable angina pectoris
* No cardiac arrhythmia
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* HIV negative
* No uncontrolled concurrent illness
* No grade 2 or greater neuropathy
* No history of allergy or anaphylaxis to mannitol, bortezomib, fludarabine, or boron
* No ongoing or active infection
* No psychiatric illness or social situation that would preclude study compliance
* At least 4 weeks since prior monoclonal antibody (MoAB) therapy:
* Patients who have received MoAB therapy within the past 3 months must have documented disease progression since receiving this therapy
* No prior allogeneic stem cell transplantation
* More than 4 weeks since prior chemotherapy
* Prior fludarabine allowed
* At least 1 week since prior steroids
* At least 3 months since prior radio-immunotherapy
* More than 4 weeks since prior radiotherapy
* No prior bortezomib
* Absolute neutrophil count at least 1,500/mm3
* Platelet count at least 75,000/mm3 (greater than 50,000/mm3 if lymphomatous bone marrow involvement is present)
* Bilirubin no greater than 2.0 mg/dL
* AST/ALT no greater than 4 times normal
* Creatinine clearance greater than 40 mL/min
* No other concurrent investigational agents or treatments for the malignancy
* No brain metastases
* OR:
Quantitation of IgM paraprotein (for Waldenstrom's macroglobulinemia patients)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brenda Cooper
Role: PRINCIPAL_INVESTIGATOR
Case Western Reserve University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mercy Medical Center
Canton, Ohio, United States
Case Western Reserve University
Cleveland, Ohio, United States
Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
Southwest General Health Center Ireland Cancer Center
Middleburg Heights, Ohio, United States
UHHS-Chagrin Highlands Medical Center
Orange, Ohio, United States
University Suburban Medical Center
South Euclid, Ohio, United States
UHHS-Westlake Medical Center
Westlake, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2009-00044
Identifier Type: REGISTRY
Identifier Source: secondary_id
ICC 3402
Identifier Type: -
Identifier Source: secondary_id
CDR0000321394
Identifier Type: -
Identifier Source: secondary_id
ICC 3402
Identifier Type: OTHER
Identifier Source: secondary_id
6126
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2009-00044
Identifier Type: -
Identifier Source: org_study_id